The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another advan
Sanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP).
Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP
Sanofi has become the latest big pharma firm to appoint a chief digital officer, choosing Ameet Nathwani to take up the position, adding onto his current role of executive vice president, c
The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a
Sanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company has forecast growth for 2019 thanks to higher than expected quarterly earnings and